Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/07/23
End: 06/01/26
Due: 06/01/27
Phase: N/A
Priority: Normal
Start: 02/10/25
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 10/31/24
End: 10/31/27
Due: 10/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression | NCT06939452 | Yongxu Jia | user2@example.com | None | 2023-06-07 | 2026-06-01 | 2027-06-01 | - | - | 2025-07-14 |
| Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study | NCT06814548 | Yongxu Jia | user2@example.com | None | 2025-02-10 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |
| Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer. | NCT06923020 | Yongxu Jia | user2@example.com | None | 2024-10-31 | 2027-10-31 | 2028-10-31 | - | - | 2025-07-14 |